November 2016, Vol. 5, No. 9 - Letter to Our Readers
Dear Colleague, With every issue, all of us on the editorial staff of Personalized Medicine in Oncology (PMO) strive to provide members of multidisciplinary oncology teams practical information about research advances and improvements within the personalized medicine spectrum that allow for more targeted and effective treatments. We are pleased to [ Read More ]
October 2016, Vol. 5, No. 8 - Letter to Our Readers
Dear Colleague, Personalizing medicine has had a tremendous impact on the way we treat illness in this country. The ability to glean information from a patient’s genetic makeup that helps us to successfully treat that patient has forever changed how we view disease. Our increased knowledge about genetic implications of [ Read More ]
August 2016, Vol. 5, No. 6 - Letter to Our Readers
Dear Colleague, On behalf of all of us at Personalized Medicine in Oncology (PMO), I hope you are enjoying the summer and finding time for the recreation necessary to return to the care of your patients with a renewed spirit. After the busy ASCO season, we have taken advantage of [ Read More ]
May 2016, Vol. 5, No. 4 - Letter to Our Readers
Dear Colleague,Over the past decade, we’ve experienced tremendous changes in the way we care for and treat patients with cancer. From research targets to available treatments; from management strategies to the very makeup of the multidisciplinary team. The publishers of Personalized Medicine in Oncology (PMO) recognize that to provide the [ Read More ]
April 2016, Vol. 5, No. 3 - Letter to Our Readers
Dear Colleague, This generation has witnessed amazing advances in the realm of precision medicine. It has learned that making personalized medicine a reality takes forward movement on many fronts—from basic research to novel drugs, from clinical trials to policy. Within our pages, we strive to present the full range of [ Read More ]
March 2016, Vol. 5, No. 2 - Letter to Our Readers
Dear Colleague, One important lesson we have learned from our work in personalizing care for oncology patients is that there are many more considerations in implementing care aside from the obvious premises of targeted therapies, companion diagnostics, and next-generation sequencing. There is an ever-broadening array of considerations that goes into [ Read More ]
February 2016, Vol. 5, No. 1 - Letter to Our Readers
Dear Colleague, It is with great enthusiasm that we present this, our first issue of 2016, to you. You will find that we are adapting our presentations to meet the learning needs of our reading community. Specifically, we are expanding our case study presentations to reflect trends in academia as [ Read More ]
December 2014, Vol 3, No 8 - Letter to Our Readers
Dear Colleague, What an incredible year for the oncology community. We have witnessed great strides in our ability to fight cancer, most notably with immunotherapeutics. As a result, we have glimpsed a possible future of cancer care that will cater to the individual patient, making personalized medicine a reality, and [ Read More ]
September 2014, Vol 3, No 6 - Letter to Our Readers
Dear Colleague, On behalf of our Editorial Board and staff, I’d like to thank you for your readership of Personalized Medicine in Oncology (PMO). We hope that you have become familiar with our mission and the content of PMO. When you flip through our pages and browse our website, you [ Read More ]
August 2014, Vol 3, No 5 - Letter to Our Readers
Dear Colleague, Until recently, cancer treatment relied solely on histological diagnosis for determining systemic therapy. Aside from considerations related to a patient’s underlying comorbidities and performance status, there was minimal deviation from an organ-of-origin–based treatment strategy. This relatively primitive understanding of malignancy failed to exploit biological and molecular differences within [ Read More ]
September 2013, Vol 2, No 6 - Letter to Our Readers
Dear Colleague, It gives us great pleasure to present this issue of Personalized Medicine in Oncology (PMO). Over the past several months, we have thoroughly examined every aspect of the journal – appearance, readability, and most importantly, editorial content. You will see the result of our efforts in the following [ Read More ]
April 2013, Vol 2, No 2 - Uncategorized
Dear Colleague, The field of oncology is changing at an unprecedented rate. Not that long ago, a few dozen chemotherapeutic agents were used to treat a wide variety of tumor types – and most of them were used empirically. It used to be relatively easy to keep current on advances [ Read More ]
Copyright 2023. Amplity Medical Communications. All Rights Reserved. Privacy Policy. Sitemap.
